J&Jís Drug for Chronic Pain Receives FDA Approval

by Kathy Jones on  August 27, 2011 at 7:33 PM Drug News
RSS Email Print This Page Comment
The US Food and Drug Administration revealed that it has approved Johnson&Johnson's tapentadol extended release drug, Nucynta ER in treating moderate-to-severe chronic pain in adults.
 J&Jís Drug for Chronic Pain Receives FDA Approval
J&Jís Drug for Chronic Pain Receives FDA Approval

The drug, manufactured by the company's Janssen Pharmaceuticals unit, has already been approved by the FDA in 50mg, 75mg and 100mg strengths and is also available in 150mg, 200mg and 250mg strengths.

Some of the common side effects after taking the drug include headache, nausea and dizziness.

Expressing his happiness at the approval, Janssen Pharmaceuticals' Dr Paul Chang said, "In clinical trials, Nucynta ER demonstrated proven efficacy for treating moderate to severe chronic pain. We are pleased with the FDA's decision to approve Nucynta ER as it represents an important new option to help people with chronic pain."



Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity Thoracic Outlet Syndrome 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.


Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive